Perfusion Cell Culture for Recombinant Protein Manufacturing

Added:

Fed-Batch Processing and the Case for Batch-Based Biomanufacturing

While perfusion cell culture offers continuous harvesting and high volumetric productivity, traditional Fed-Batch processing remains the dominant paradigm in commercial recombinant protein manufacturing. Critics of perfusion highlight its significant operational complexity, elevated contamination risks over extended run times, and mechanical vulnerabilities such as membrane fouling in cell retention devices. Additionally, perfusion requires massive volumes of media, complicating supply chains, increasing cost of goods, and generating substantial liquid waste. Fed-batch systems, conversely, offer simpler process validation, straightforward scale-up, lower initial capital expenditure, and a deeply established regulatory track record, making them a more robust and predictable choice for many biopharmaceutical pipelines.

Fundamental differences between batch, fed-batch, and continuous cell culture operating modes.
Principles of recombinant protein expression and mammalian host cell line biology (e.g., CHO cells).
Basic cell culture kinetics, including cell growth phases, specific growth rate, and metabolic waste accumulation (such as lactate and ammonia).
Core concepts of upstream bioprocessing, including basic bioreactor components and aseptic operation techniques.
Advanced engineering principles of cell retention devices, specifically Alternating Tangential Flow (ATF) and Tangential Flow Filtration (TFF) mechanics.
Integrated Continuous Biomanufacturing: aligning continuous upstream perfusion with continuous downstream purification processes.
Implementation of Process Analytical Technology (PAT) and real-time sensor integration for automated perfusion control.
Techno-economic and lifecycle analysis of perfusion-based facilities compared to traditional large-scale fed-batch facilities.
127 views1likes17:14@celcorsystems1890Original Release: 2020-04-18

Perfusion cell culture for recombinant protein manufacturing relies on two key parameters: perfusion rate (vessel volumes per reactor volume per day) and cell-specific perfusion rate (media consumption normalized to cell density), with the bleed rate controlling cell density to maximize yield; cell retention devices including tangential flow filtration systems (ATF and TFF) are essential for maintaining stable operation by preventing cell loss while providing sufficient aeration and minimizing shear stress, with optimal performance requiring careful balancing of cell growth, bleed rate, and process productivity.